e-learning
resources
Paris 2018
Tuesday, 18.09.2018
Notable Studies in Asthma
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria
K. Marth (Vienna, Austria), A. Renner (Vienna, Austria), K. Patocka (Vienna, Austria), W. Pohl (Vienna, Austria)
Source:
International Congress 2018 – Notable Studies in Asthma
Session:
Notable Studies in Asthma
Session type:
Oral Presentation
Number:
3568
Disease area:
Airway diseases
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
K. Marth (Vienna, Austria), A. Renner (Vienna, Austria), K. Patocka (Vienna, Austria), W. Pohl (Vienna, Austria). Late Breaking Abstract - Patients with severe eosinophilic asthma benefit from the treatment with Anti-IL-5 Reslizumab – a real life study from Austria. 3568
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
The Relationship Between Functional Status and Fatigue After COVID-19 Infection
Late Breaking Abstract - Implications of treatable traits and treatment choices on exacerbation risk in moderate-severe asthma
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Related content which might interest you:
Late Breaking Abstract - Daily physical activity in patients with severe eosinophilic asthma and the effect of anti-IL5 therapy.
Source: International Congress 2018 – New pharmacological strategies in airway diseases
Year: 2018
Late Breaking Abstract - Early response to benralizumab in Canadians with severe eosinophilic asthma
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
Late Breaking Abstract - The impact of treatment with mepolizumab on airway remodeling in patients with severe eosinophilic asthma.
Source: Virtual Congress 2021 – Asthma clinical trials and real-life studies
Year: 2021
Late Breaking Abstract - Clinical characteristics and lung function trends of severe eosinophilic asthma patients unresponsive to Mepolizumab
Source: International Congress 2019 – Blood eosinophils and more in airway diseases
Year: 2019
Late Breaking Abstract - International, prospective real-world study of mepolizumab in patients with severe asthma at one year: REALITI-A
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021
Late Breaking Abstract - Daily physical activity in patients with severe asthma and the effect of anti-IL5 therapy.
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Late Breaking Abstract - Long-term safety & durability of mepolizumab in life-threatening/seriously debilitating severe eosinophilic asthma (SEA): COSMEX
Source: International Congress 2018 – Notable Studies in Asthma
Year: 2018
One year following a real life experience of omalizumab for moderate to severe persistent allergic asthma in Malta
Source: Annual Congress 2013 –Asthma drugs: new findings
Year: 2013
Late Breaking Abstract - Dose-ranging study of mepolizumab in eosinophilic COPD
Source: International Congress 2017 – Late-breaking findings in asthma and COPD
Year: 2017
Late Breaking Abstract - Efficacy of oral prednisolone in patients with stable severe eosinophilic asthma (SEA) treated with Mepolizumab
Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma
Year: 2020
Late Breaking Abstract - Benralizumab treatment strongly reduces blood basophils in patients with severe eosinophilic asthma
Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Year: 2019
Late Breaking Abstract - Response to mepolizumab in patients with severe CRSwNP using EUFOREA 2021 criteria
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021
Late Breaking Abstract - Determinants of disease control in patients with severe COPD. The CLAVE Study
Source: International Congress 2019 – Clinical approach to asthma management
Year: 2019
Real-life experience with mepolizumab in the French early access program for severe eosinophilic asthma
Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies
Year: 2019
Late Breaking Abstract - Efficacy and safety of tezepelumab in adults with severe asthma: A randomized phase 2 study
Source: International Congress 2017 – Late-breaking studies in asthma and COPD
Year: 2017
Late Breaking Abstract - Six years experience of Pirfenidone treatment in IPF patients in Crete: Real life data
Source: International Congress 2017 – Idiopathic pulmonary fibrosis (IPF): treatment highlights
Year: 2017
Late Breaking Abstract - Mepolizumab reduces exacerbations in eosinophilic COPD
Source: International Congress 2017 – Late-breaking studies in asthma and COPD
Year: 2017
Late Breaking Abstract - Two-year cumulative oral corticosteroid exposure in severe eosinophilic asthma before and after anti-IL-5 therapy
Source: Virtual Congress 2021 – Advances in asthma treatment
Year: 2021
Late Breaking Abstract - The burden of intermittent oral corticosteroid use in asthma
Source: Virtual Congress 2021 – Asthma treatment: clinical and translational science
Year: 2021
Late Breaking Abstract: Tiotropium improves lung function in patients with severe uncontrolled asthma
Source: Annual Congress 2010 - Treatment options for asthma
Year: 2010
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept